Celcuity
Clinical-stage biotechnology company that seeks to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy.
Launch date
Employees
Market cap
CAD756m
Enterprise valuation
CAD502m (Public information from Sep 2024)
Share price
$15.01 CELC
Hamel Illinois (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | 5.0m | 3.9m | 61.7m |
| % growth | - | - | - | - | - | (23 %) | 1501 % |
| EBITDA | (9.5m) | (28.3m) | (38.3m) | (58.3m) | (107m) | (129m) | (149m) |
| % EBITDA margin | - | - | - | - | (2117 %) | (3345 %) | (242 %) |
| Profit | (9.5m) | (29.6m) | (40.4m) | (63.8m) | (99.0m) | (143m) | (147m) |
| % profit margin | - | - | - | - | (1964 %) | (3713 %) | (238 %) |
| EV / revenue | - | - | - | - | 91.5x | 153.2x | 9.6x |
| EV / EBITDA | -10.0x | -6.9x | -7.9x | -6.3x | -4.3x | -4.6x | -4.0x |
| R&D budget | 7.7m | 25.8m | 35.3m | 60.6m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$4.0m | Series A | ||
| N/A | $5.2m | Early VC | |
* | N/A | $5.8m | Convertible |
| N/A | $2.6m | Convertible | |
| N/A | N/A | IPO | |
| N/A | $5.8k | Post IPO Equity | |
| N/A | $3.8k | Convertible | |
| N/A | $24.0m | Post IPO Equity | |
* | $100m | Post IPO Equity | |
* | $100m | Private Placement VC | |
* | N/A | $50.0m | Private Placement VC |
* | N/A | Post IPO Equity | |
* | $61.7m | Post IPO Debt | |
| Total Funding | CAD229m | ||
Related Content
Recent News about Celcuity
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.